CGH-2466
CGH-2466 is a novel investigational compound currently under research for its potential therapeutic applications in the treatment of neurodegenerative diseases. This compound has shown promise in preclinical studies, particularly in models of Alzheimer's disease and Parkinson's disease.
Mechanism of Action[edit | edit source]
CGH-2466 is believed to exert its effects through modulation of the neurotransmitter systems in the brain. It acts as a selective agonist at the serotonin receptor subtype 5-HT6, which is implicated in cognitive processes. By enhancing serotonergic activity, CGH-2466 may improve cognitive function and slow the progression of neurodegenerative symptoms.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of CGH-2466 has been characterized in animal models. It exhibits good oral bioavailability and penetrates the blood-brain barrier effectively. The compound is metabolized primarily in the liver and has a half-life conducive to once-daily dosing.
Clinical Trials[edit | edit source]
CGH-2466 is currently in Phase II clinical trials. Initial results have demonstrated a favorable safety profile and preliminary efficacy in improving cognitive function in patients with mild to moderate Alzheimer's disease. Further studies are ongoing to evaluate its long-term effects and potential benefits in other neurodegenerative conditions.
Potential Side Effects[edit | edit source]
As with any investigational drug, CGH-2466 may have side effects. Commonly reported adverse effects in clinical trials include mild gastrointestinal disturbances, headache, and dizziness. Serious adverse events have been rare.
Research and Development[edit | edit source]
The development of CGH-2466 is being spearheaded by a consortium of academic institutions and pharmaceutical companies. The research is funded by grants from various governmental and non-governmental organizations dedicated to advancing treatments for neurodegenerative diseases.
Future Directions[edit | edit source]
Future research on CGH-2466 will focus on elucidating its precise mechanism of action, optimizing its pharmacological properties, and expanding its therapeutic indications. There is also interest in exploring its potential synergistic effects when used in combination with other neuroprotective agents.
Also see[edit | edit source]
- Neurodegenerative disease
- Alzheimer's disease
- Parkinson's disease
- Serotonin receptor
- Blood-brain barrier
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
